No Data
Berry Genomics Co.,Ltd (SZSE:000710) Shares Fly 37% But Investors Aren't Buying For Growth
Is Berry GenomicsLtd (SZSE:000710) Using Debt In A Risky Way?
Berry Genomics (000710.SZ): The related AI services that have been formed are currently offered to customers as an added value part of the overall Business.
On March 4th, Gelonghui reported that Berry Genomics (000710.SZ) published an announcement regarding abnormal fluctuations in Stocks trading. The company has noticed a high market interest in the AI Medical Concept recently. The main Business of the company still focuses on the sales of reagents and equipment, medical testing services, and basic research services. AI technology has not yet become a core component of its business, nor has it generated direct income. The related AI services that have been developed are currently provided to customers as an added value of the overall Business. Among the Asia Vets products, the two self-developed intelligent platforms that are already in use, the CNVisi intelligent interpretation report system and WESisi platform, were released in 2020.
Analysis of China's Potential $16.4 Bn Genetic Testing Market, 2025-2033 - Featuring Key Players BGI, Berry Genomics Co., Daan Gene Co., WuXi NextCODE, Annoroad Gene Technology Co., and WuXi PharmaTech
Berry Genomics (000710.SZ): Currently connected to various open-source models such as Deepseek, Qianwen, llama, Zhipu AI, BiomedGPT, and LucaOne.
On February 12, Longhu reported that Berry Genomics (000710.SZ) recently expressed during an investor relations event that the company has now accessed multiple open-source models such as Deepseek, Qianwen, Llama, Asia Vets AI, BiomedGPT, and LucaOne. Through the application of large models, the company aims to enhance operational efficiency, reduce operational costs, and provide higher quality services to its clinical clients. To date, Berry has reached a global strategy with several large medical institutions and plans to develop AI Big Data construction based on molecular diagnostics and genetic disease consulting, gradually expanding into other fields, expected within the year.
Berry GenomicsLtd (SZSE:000710) Shareholder Returns Have Been Decent, Earning 83% in 1 Year
We Think Berry GenomicsLtd (SZSE:000710) Has A Fair Chunk Of Debt
